Schottke H, Saeger W, Lüdecke D K, Caselitz J
Pathol Res Pract. 1986 Jun;181(3):280-90. doi: 10.1016/S0344-0338(86)80104-2.
19 macroprolactinomas and 1 microprolactinoma were analysed by light microscopical, immunohistological and ultrastructural as well as morphometrical methods. 8 adenomas were removed from patients who were treated preoperatively with bromocriptine and/or Lisurid for different periods. 18 of 20 adenomas were positive for PRL on the immunohistological level. One case was negative. This patient showed a good response to the pharmacological treatment. The ultrastructure of this case revealed many secretory granules. A morphometric analysis of the ultrastructure could be performed in 19 cases; 1 case had to be excluded because of large necrotic areas. The following qualitative significant alterations after the treatment could be established: Reduction of the volume density of the rough endoplasmatic reticulum; Reduction of the size of the granula diameter; Increase of the volume density of the more irregular and indented nuclei. Other alterations were as follows: Reduction of the nuclear size; Increase of the number of secretory granules and of the volume density of lysosomes. These changes were to be observed in most of those tumors which responded to the dopamine agonist treatment. The non-responding adenomas and one which was removed 6 days after having discontinued a successful preoperative medical therapy were similar to the untreated adenomas. The results display the influence of dopamine agonist on the hormone synthesis, release and degradation in PRL secreting adenoma cells.
采用光学显微镜、免疫组织化学、超微结构以及形态计量学方法对19例大泌乳素瘤和1例微泌乳素瘤进行了分析。8例腺瘤取自术前接受不同疗程溴隐亭和/或利舒脲治疗的患者。20例腺瘤中有18例在免疫组织化学水平上PRL呈阳性。1例为阴性。该患者对药物治疗反应良好。该病例的超微结构显示有许多分泌颗粒。对19例病例进行了超微结构的形态计量分析；1例因大片坏死区域而被排除。治疗后可确定以下定性的显著改变：粗面内质网体积密度降低；颗粒直径减小；更不规则且有凹陷的细胞核体积密度增加。其他改变如下：核大小减小；分泌颗粒数量增加以及溶酶体体积密度增加。在大多数对多巴胺激动剂治疗有反应的肿瘤中观察到了这些变化。无反应的腺瘤以及1例在术前成功的药物治疗停药6天后切除的腺瘤与未治疗的腺瘤相似。结果显示了多巴胺激动剂对泌乳素分泌性腺瘤细胞中激素合成、释放和降解的影响。
